

Numab Nominates Burkhard Becher Scientific Advisor

Wädenswil, Switzerland, December 18, 2012 – Numab AG, a Swiss Biotech company, today announces the appointment of Prof. Burkhard Becher to Numab’s Scientific Advisory Board. Burkhard Becher is a world leading immunologist, whose research aims at understanding the development of tissue-specific autoimmunity, tumor immunology and cytokine biology. In 2003, he was recruited as Assistant Professor to the University Hospital of Zurich and in 2008, he became full professor and co-chair at the Institute of Experimental Immunology at the University of Zurich. His fundamental contribution to the field has been published in the leading scientific journals. Most recently he was awarded the Robert Bing Price for Neuroscience, the Biogen Dompé MS-Research Price and the Prof. Max Cloëtta Award, adding to the various honors he has received for his scientific work.

Burkhard Becher commented his appointment: “What I found most exciting about Numab, was their program to develop an innovative and potentially game-changing therapeutic that holds the promise for superior effect size and prolonged effect duration in a variety of chronic inflammatory and autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowels disease.” David Urech, CSO, co-CEO and co-founder of Numab, added: “We are very proud to have Professor Becher in our Advisory Board. His great expertise in the field of autoimmunity will be key for the development of our autoimmune project”.

About Numab AG:

Numab is a privately-owned Swiss biotech company located in Wädenswil, Zurich. The Company is managed by an experienced team and applies its breakthrough antibody discovery technology to fuel its own pipeline and the pipelines of its partners in the pharmaceutical industry with innovative antibody-based therapeutics. The technology was developed to generate antibodies against notoriously difficult targets and differentiates from conventional antibody technologies through its unrivaled probability of success in discovery and the ability to engineer desired functionalities into a molecule. Numab pursues two proprietary projects to develop innovative antibody-based therapeutics in the areas of chronic inflammatory diseases and severe chronic pain.

For further information please contact:

Oliver Middendorp
o.middendorp@numab.com

or visit:

www.numab.com